Gliatilin (Choline alfoscerate)

Active substance:

choline alfoscerate 400 mg;

Excipients:

 purified water;

glycerol; 

Capsule shell:

 gelatin;

ezitol;

sorbitans;

sodium ethyl parahydroxybenzoate;

sodium propyl parahydroxybenzoate;

titanium dioxide (E171);

iron (III) metahydroxide (E172)

• acute TBI with a predominantly stem level lesion (impaired consciousness, coma, focal hemispheric symptoms, symptoms of damage to the brain stem);
• ischemic (acute and recovery period) and hemorrhagic stroke (recovery period);
• degenerative and involutional psycho-organic syndromes and the consequences of cerebrovascular insufficiency, such as primary and secondary disorders of memory functions, characterized by impaired memory, confusion, disorientation, decreased motivation, initiative, ability to concentrate;
• changes in the emotional and behavioral sphere: emotional lability, increased irritability, decreased interest, senile pseudomelancholy;
• multi-infarct dementia.

Hypersensitivity to the drug.

Nausea (as a result of dopaminergic activation), in this case, the dose of the drug should be reduced.

Allergic reactions are possible.

Drug interactions of the drug Gliatilin not established.

Inside, before meals.

In case of chronic cerebrovascular insufficiency, changes in the emotional and behavioral sphere and multi-infarction dementia: inside - 400 mg (1 capsule) 3 times a day.

The duration of therapy is 3-6 months.

Symptoms: nausea.

When this symptom appears, it is recommended to reduce the dose of the drug.

In experimental studies, no mutagenic effect of the drug has been established.

- The effect on the ability to drive vehicles and control mechanisms Gliatilin does not affect the patient's ability to engage in potentially hazardous activities.